Christopher Wolfe
Optometrist · Omaha, NENPI 1427219617
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.8%), consulting fees and grants — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Coopervision Inc. at 32.1% of the total. Among optometrist clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $455.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$49K
- AbbVie$48K
- Astellas Pharma US Inc$19K
- Sight Sciences, Inc.$17K
- Johnson & Johnson Surgical Vision, Inc.$7K
- Lumenis BE Inc$5K
- plus $8K from 17 others
What the payments were for
- Consulting fees$53,14934%
- Speaking & faculty fees$58,35338%
- Grants$16,00010%
- Travel & lodging$15,56810%
- Food & beverage$11,2057%
- Education$70%
- Entertainment$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 96 | $49,461 |
| AbbVie(2 entities) | 75 | $48,344 |
| Astellas Pharma US Inc | 15 | $19,301 |
| Sight Sciences, Inc. | 24 | $17,153 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $7,173 |
| Lumenis BE Inc | 1 | $5,200 |
| Optos, Inc. | 3 | $1,057 |
| LKC Technologies, Inc. | 9 | $955 |
| Carl Zeiss Meditec, Inc. | 2 | $894 |
| Sun Pharmaceutical Industries Inc. | 17 | $767 |
| Maculogix, Inc. | 7 | $765 |
| Topcon Healthcare, Inc. | 7 | $742 |
| Alcon | 19 | $713 |
| Bausch & Lomb Americas Inc. | 14 | $608 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $535 |
| Novartis | 6 | $219 |
| Biotissue Holdings Inc. | 3 | $108 |
| Oyster Point Pharma, Inc. | 4 | $103 |
| Organogenesis Inc. | 5 | $96 |
| Amgen | 2 | $62 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $20 |
| Immunogen, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VUITY$28,301
- MiSight Contact Lens$22,351
- Izervay$19,193
- RESTASIS MULTIDOSE$16,000
- MyDay Contact Lens$10,323
- TearCare SmartLid$8,397
- TEARCARE(TM) (2.2) SYSTEM KIT$8,397
- TearCare$8,335
- One Series Ultra IOL Delivery System$6,420
- Multiple Brands Contact Lens$5,382
- optilight$5,200
- Non-Product Brand Specific$2,321
- PANORAMIC OPHTHALMOSCOPE$2,000
- Clariti Contact Lens$1,747
- CVI Contact Lens$1,708
- OCT OPHTHALMOSCOPE$1,000
- NFC-700$1,000
- LUMIGAN$1,000
- CIRRUS HD-OCT$880
- AdaptDx$608
How this compares
$154,313 in reported general payments places this provider in the 95th percentile of 383 optometrist providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 30 | $26,693 |
| XiidraLifitegrast | 35 | $26,406 |
| Latanoprost | 110 | $1,603 |
| Prednisolone Acetate | 19 | $793 |
| Timolol Maleate | 32 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $48,344 | $26,69330 claims |
| Bausch & Lomb Americas Inc.Xiidra | $608 | $26,40635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 383 optometrist providers in Nebraska.
Other optometrist in Omaha
- Mark ToelleOmaha$10K
- John GoertzOmaha$8K
- Jordan ArensOmaha$7K
- Holly TernusOmaha$6K
- Marsha KubicaOmaha$6K
- Delaney KentOmaha$5K
- Adam WalterOmaha$5K
- Kelly RobertsonOmaha$5K
- Kristen WaltonOmaha$5K
- Kristin ReedOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.